東華大學圖書館 |

Language: English

Help

回圖書館首頁

手機版館藏查詢

Back

Switch To: Labeled | MARC Mode | ISBD

Development of Biomaterials for Drug...

de Castro, Raquel.

Linked to FindBook

Google Book

Amazon

博客來

Development of Biomaterials for Drug Delivery.

Record Type:	Electronic resources : Monograph/item
Title/Author:	Development of Biomaterials for Drug Delivery./
Author:	de Castro, Raquel.
Published:	Ann Arbor : ProQuest Dissertations & Theses, : 2021,
Description:	117 p.
Notes:	Source: Dissertations Abstracts International, Volume: 82-12, Section: B.
Contained By:	Dissertations Abstracts International82-12B.
Subject:	Nanotechnology. -
Online resource:	https://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=28493757
ISBN:	9798505536407

Development of Biomaterials for Drug Delivery.
de Castro, Raquel.

Development of Biomaterials for Drug Delivery. - Ann Arbor : ProQuest Dissertations & Theses, 2021 - 117 p.

Source: Dissertations Abstracts International, Volume: 82-12, Section: B.

Thesis (Ph.D.)--University of Arkansas, 2021.

This item must not be sold to any third party vendors.

Drug delivery systems (DDS) have highly evolved in the last decades with the development of hydrogels and nanoparticles. However, high systemic uptake, side effects, low bioavailability, and encapsulation efficiency continue to be a major hurdle faced by such DDSs. Nanoparticles and hydrogels can be specifically designed for targeted DDSs to mitigate some of the problems. This dissertation aimed to design two DDSs for ocular drug delivery and one for cancer treatment. The first project sought to develop chitosan nanoparticles (Cs-NP) using PEGDA as a copolymer to encapsulate gentamicin (GtS) for ocular drug delivery. Cs-NPs contain positive charges that can interact with negatively charged ocular proteins to increase the NP residence time. Simultaneously, ocular enzymes degrade the chitosan β-(1→4)-glycosidic bonds to release GtS at the eye's surface, therefore, preventing premature release of GtS. PEGDA was used to increase drug encapsulation by shielding the repelling forces of like charges between Cs and GtS. The data shows PEGDA does not hinder enzymatic degradation while increasing drug encapsulation efficiency and producing more stable and homogeneous particles. The second project utilized Michael's reaction to crosslink Cs, Cs-NPs, and PEGDA to produce a film designed for ocular drug delivery. The film serves as an anchor for the NPs to prevent drug removal by tears and blinking. The data shows that crosslinking of Cs and PEGDA does not affect lysozyme activity, and NPs could successfully release GtS without affecting GtS activity. Finally, the third project sought to compare the cytotoxicity of the polysaccharide fucoidan (FU) encapsulated into chitosan nanoparticles (CFU) and without encapsulation (free-FU) and their effects on two cancer cell lines. The results indicate that free-FU has very little toxicity to MDA-MB-231 cancer cells compared to MCF-7. However, cytotoxicity to MDA-MB-231 cells was increased by delivering encapsulated FU. Free-FU can enter MCF-7 cells using surface receptors that are not present in MDA-MB-231 cells. Therefore, by encapsulating FU into Cs-NPs, cytotoxicity can be increased as Cs-NPs containing FU are endocytosed into the MDA-MB-231 cells.

ISBN: 9798505536407Subjects--Topical Terms:

526235
Nanotechnology.
Subjects--Index Terms:

Cancer

Development of Biomaterials for Drug Delivery.
LDR:03356nmm a2200385 4500 001 2281649
005 20210920103608.5
008 220723s2021 ||||||||||||||||| ||eng d
020 $a 9798505536407
035 $a (MiAaPQ)AAI28493757
035 $a AAI28493757
040 $a MiAaPQ $c MiAaPQ
100 1 $a de Castro, Raquel. $0 (orcid)0000-0003-0110-3143 $3 3560331
245 1 0 $a Development of Biomaterials for Drug Delivery.
260 1 $a Ann Arbor : $b ProQuest Dissertations & Theses, $c 2021
300 $a 117 p.
500 $a Source: Dissertations Abstracts International, Volume: 82-12, Section: B.
500 $a Advisor: Thompson, Audie K.
502 $a Thesis (Ph.D.)--University of Arkansas, 2021.
506 $a This item must not be sold to any third party vendors.
520 $a Drug delivery systems (DDS) have highly evolved in the last decades with the development of hydrogels and nanoparticles. However, high systemic uptake, side effects, low bioavailability, and encapsulation efficiency continue to be a major hurdle faced by such DDSs. Nanoparticles and hydrogels can be specifically designed for targeted DDSs to mitigate some of the problems. This dissertation aimed to design two DDSs for ocular drug delivery and one for cancer treatment. The first project sought to develop chitosan nanoparticles (Cs-NP) using PEGDA as a copolymer to encapsulate gentamicin (GtS) for ocular drug delivery. Cs-NPs contain positive charges that can interact with negatively charged ocular proteins to increase the NP residence time. Simultaneously, ocular enzymes degrade the chitosan β-(1→4)-glycosidic bonds to release GtS at the eye's surface, therefore, preventing premature release of GtS. PEGDA was used to increase drug encapsulation by shielding the repelling forces of like charges between Cs and GtS. The data shows PEGDA does not hinder enzymatic degradation while increasing drug encapsulation efficiency and producing more stable and homogeneous particles. The second project utilized Michael's reaction to crosslink Cs, Cs-NPs, and PEGDA to produce a film designed for ocular drug delivery. The film serves as an anchor for the NPs to prevent drug removal by tears and blinking. The data shows that crosslinking of Cs and PEGDA does not affect lysozyme activity, and NPs could successfully release GtS without affecting GtS activity. Finally, the third project sought to compare the cytotoxicity of the polysaccharide fucoidan (FU) encapsulated into chitosan nanoparticles (CFU) and without encapsulation (free-FU) and their effects on two cancer cell lines. The results indicate that free-FU has very little toxicity to MDA-MB-231 cancer cells compared to MCF-7. However, cytotoxicity to MDA-MB-231 cells was increased by delivering encapsulated FU. Free-FU can enter MCF-7 cells using surface receptors that are not present in MDA-MB-231 cells. Therefore, by encapsulating FU into Cs-NPs, cytotoxicity can be increased as Cs-NPs containing FU are endocytosed into the MDA-MB-231 cells.
590 $a School code: 0011.
650 4 $a Nanotechnology. $3 526235
650 4 $a Polymer chemistry. $3 3173488
650 4 $a Materials science. $3 543314
653 $a Cancer
653 $a Drug delivery
653 $a Hydrogels
653 $a Nanoparticles
653 $a Polymer
653 $a Polysaccharide
690 $a 0652
690 $a 0495
690 $a 0794
710 2 $a University of Arkansas. $b Cell & Molecular Biology. $3 2091895
773 0 $t Dissertations Abstracts International $g 82-12B.
790 $a 0011
791 $a Ph.D.
792 $a 2021
793 $a English
856 4 0 $u https://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=28493757